MedTrace Logo

Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea

NCT06952517 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-05-06

No results posted yet for this study

Summary

To demonstrate the efficacy of Clascoterone cream 1% in reducing the size of sebaceous glands in study participants with acneiform rosacea.

Conditions

  • Papular-pustular Rosacea
  • Papulopustular Rosacea (PPR)
  • Papulopustular Rosacea

Interventions

DRUG

Clascoterone Cream 1%

Clascoterone 1% cream

Sponsors & Collaborators

  • Sun Pharmaceutical Industries Limited

    collaborator INDUSTRY

  • Narrows Institute for Biomedical Research

    lead OTHER

Principal Investigators

  • Jared Jagdeo, MD MS · SUNY Downstate Health Sciences University Department of Dermatology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-03-14
Primary Completion
2025-09-01
Completion
2025-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06952517 on ClinicalTrials.gov